Bringing Treatment Home: Daratumumab Administration by Danish Community Nurses in Multiple Myeloma—A Mixed-Method Study

The expansion of home-based cancer care aims to reduce hospital burden while supporting patient-centered treatment. For patients with multiple myeloma who require long-term therapy and frequent hospital visits, community-based treatment may improve flexibility and quality of life. This prospective mixed-methods study explored the feasibility of community nurses administering subcutaneous daratumumab in patients’ homes or local healthcare clinics. Nineteen patients, nine community nurses, and four hospital healthcare professionals participated in interviews or focus groups. Patient-reported quality of life was assessed using the EORTC QLQ-C30. Most patients preferred home- or local-based administration, citing greater comfort, reduced travel, and a greater sense of normalcy. Community nurses and hospital professionals considered the model feasible and safe when supported by structured training, clear guidelines, and effective communication. However, medication delivery and care coordination created logistical challenges that reduced flexibility for some patients. Quality-of-life scores showed no consistent differences between home- and hospital-based treatment. Home administration should consider clinical stability, cognitive function, patient preferences, and daily routines. Successful implementation requires standardized training, clear roles, reliable communication, and efficient workflows. Home-based daratumumab should be offered as an individualized option within integrated cancer care rather than as a universal replacement for hospital-based treatment.